• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen.

作者信息

Goto Naoe, Tsurumi Hisashi, Takemura Masao, Matsumoto Takuro, Shibata Yuhei, Mabuchi Ryoko, Nakamura Nobuhiko, Nakamura Hiroshi, Yamada Tetsuya, Seishima Mitsuru, Takami Tsuyoshi, Takeuchi Tamotsu, Moriwaki Hisataka

机构信息

First Department of Internal Medicine, Gifu University Graduate School of Medicine.

出版信息

J Clin Exp Hematop. 2014;54(2):117-27. doi: 10.3960/jslrt.54.117.

DOI:10.3960/jslrt.54.117
PMID:25318944
Abstract
摘要

相似文献

1
Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen.血清可溶性肿瘤坏死因子受体1水平与接受CHOP或R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者的预后相关。
J Clin Exp Hematop. 2014;54(2):117-27. doi: 10.3960/jslrt.54.117.
2
Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.可溶性肿瘤坏死因子受体 2 血清水平与接受 R-CHOP 方案治疗的弥漫性大 B 细胞淋巴瘤患者的预后相关。
Eur J Haematol. 2013 Oct;91(4):322-31. doi: 10.1111/ejh.12139. Epub 2013 Jul 7.
3
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松治疗周期中的外周血绝对淋巴细胞/单核细胞比值可预测弥漫性大B细胞淋巴瘤的临床结局。
Leuk Lymphoma. 2014 Dec;55(12):2728-38. doi: 10.3109/10428194.2014.893313. Epub 2014 Mar 19.
4
Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases.弥漫性大B细胞淋巴瘤患者接受含或不含利妥昔单抗的CHOP样方案治疗时，可溶性白细胞介素-2受体α（sIL-2Rα）的预后重要性及其与淋巴瘤细胞表面白细胞介素-2受体α（CD25）表达的关系：338例回顾性分析
J Clin Exp Hematop. 2013;53(3):197-205. doi: 10.3960/jslrt.53.197.
5
Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial.在GELA LNH-985试验中接受R-CHOP或CHOP治疗的老年患者的十年相对生存率及死亡原因
Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):151-4. doi: 10.1016/j.clml.2011.11.004. Epub 2012 Feb 1.
6
Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.血清白细胞介素-18 水平与接受 CHOP 或 R-CHOP 方案治疗的弥漫性大 B 细胞淋巴瘤患者的预后相关。
Eur J Haematol. 2011 Sep;87(3):217-27. doi: 10.1111/j.1600-0609.2011.01649.x. Epub 2011 Jul 26.
7
Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.p53 异常对接受 R-CHOP 治疗的弥漫性大 B 细胞淋巴瘤患者的预后影响。
Int J Oncol. 2011 Dec;39(6):1413-20. doi: 10.3892/ijo.2011.1170. Epub 2011 Aug 18.
8
The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma.R-CHOP方案的初始剂量强度和相对剂量强度对老年弥漫性大B细胞淋巴瘤患者预后的影响。
Leuk Lymphoma. 2017 Mar;58(3):736-739. doi: 10.1080/10428194.2016.1211279. Epub 2016 Aug 11.
9
Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松治疗的弥漫性大B细胞淋巴瘤患者流式细胞术检测的人类白细胞抗原-DR表达及肿瘤相关巨噬细胞：回顾性队列研究
Leuk Lymphoma. 2014 Dec;55(12):2721-7. doi: 10.3109/10428194.2014.893311. Epub 2014 Mar 19.
10
Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.在接受利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松治疗的弥漫性大B细胞淋巴瘤中，Ki-67表达的预后影响仅限于老年晚期患者的非生发中心B细胞样亚型。
Leuk Lymphoma. 2015;56(9):2630-6. doi: 10.3109/10428194.2015.1004169. Epub 2015 Feb 4.